News Related to Tempus AI, Inc.

Related coverage linked through entity extraction aliases.

Tempus AI and Merck Expand Collaboration on AI-Driven Precision Medicine

Mar 04, 2026

Tempus AI and Merck announced an expanded multi-year collaboration to accelerate discovery and development of precision medicine biomarkers using AI and multimodal datasets, focusing on oncology and potentially broader therapeutic areas.

Oncology Precision Medicine Market to Reach $366.53 Billion by 2033

Feb 24, 2026

The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.